DecisionHealth, DecisionHealth - 2004 Issue 2 (February)
Least costly alternative policy not expected to see much use
Subscribe or sign in to view the full article.
Article Overview
This premium article discusses a Medicare reimbursement policy issue affecting Part B drugs in the wake of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. It outlines the least costly alternative concept, contrasts differing interpretations of CMS authority, and explains why the policy was thought to have limited future use. The piece is relevant to coders, billing staff, reimbursement analysts, and others tracking Medicare drug payment policy and CMS guidance.
Why This Topic Matters
Understanding this policy affects how Medicare drug reimbursement is interpreted and managed for Part B services. The article helps readers follow CMS payment policy changes and the broader reimbursement environment for physician-administered drugs.
What You Will Learn
- How the least costly alternative policy fits into Medicare Part B drug reimbursement
- Why the MMA led to differing interpretations of CMS reimbursement authority
- What policy changes were expected to affect physician-administered drug payment
- How CMS and congressional staff perspectives differed on the policy's future
Who Should Read This
- Medical coders
- Billing specialists
- Reimbursement analysts
- Practice administrators
- Healthcare compliance staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com